Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4118179 | 0.87 | HTR6 (0.37) | PKMTP53PDE10APOLBLMNA | |
| SCHEMBL4118513 | 0.86 | MAPT (0.37) | TSHRTP53L3MBTL1POLBALDH1A1 | |
| SCHEMBL4119376 | 0.85 | GRM2 (0.41) | TSHRTP53L3MBTL1POLBLMNA | |
| Hydrochloric Acid SCHEMBL4125444 | 0.85 | PKM (0.44) | PKMRAB9ATSHRTP53L3MBTL1 | |
| SCHEMBL4137538 | 0.84 | TSHR (0.42) | PKMRAB9ATSHRTP53L3MBTL1 | |
| SCHEMBL4129177 | 0.83 | KAT6A (0.39) | RAB9ATSHRTP53POLBALDH1A1 | |
| SCHEMBL4132039 | 0.82 | NPC1 (0.43) | RAB9ATSHRL3MBTL1POLBALDH1A1 | |
| SCHEMBL4119867 | 0.81 | MAPT (0.41) | TP53LMNAALDH1A1SMN1; SMN2HTT | |
| SCHEMBL3649312 | 0.81 | TSHR (0.40) | PKMRAB9ATSHRTP53L3MBTL1 | |
| SCHEMBL3649310 | 0.79 | TSHR (0.40) | PKMRAB9ATSHRTP53L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | PKM 4108/4885RAB9A 167/4885TSHR 1878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.